- Home
- PRME vs BSX Comparison
PRME vs BSX Comparison
Compare PRME & BSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRME | BSX |
|---|---|---|
| Founded | 2019 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 666.1M | 137.8B |
| IPO Year | 2022 | 1992 |
Fundamental Metrics
Financial Performance| Metric | PRME | BSX |
|---|---|---|
| Price | $3.46 | $94.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 17 |
| Target Price | $6.42 | ★ $125.88 |
| AVG Volume (30 Days) | 3.8M | ★ 9.3M |
| Earning Date | 11-07-2025 | 02-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.68 |
| EPS | N/A | ★ 1.87 |
| Revenue | $5,977,000.00 | ★ $19,349,000,000.00 |
| Revenue This Year | $111.80 | $21.05 |
| Revenue Next Year | N/A | $11.44 |
| P/E Ratio | ★ N/A | $50.65 |
| Revenue Growth | ★ 647.13 | 21.61 |
| 52 Week Low | $1.11 | $85.98 |
| 52 Week High | $6.94 | $109.50 |
Technical Indicators
Market Signals| Indicator | PRME | BSX |
|---|---|---|
| Relative Strength Index (RSI) | 41.10 | 42.88 |
| Support Level | $3.29 | $95.55 |
| Resistance Level | $4.12 | $96.33 |
| Average True Range (ATR) | 0.24 | 1.45 |
| MACD | -0.02 | 0.23 |
| Stochastic Oscillator | 17.12 | 62.92 |
Price Performance
Historical ComparisonAbout PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
About BSX Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.